Analysts See More Than 77% Upside for Eupraxia Pharmaceuticals (EPRX), Here’s Why

​Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) is one of the Best Up and Coming Canadian Stocks to Buy. Analysts see more than 77% upside for Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX). This bullish sentiment comes after the clinical-stage biotechnology company reported promising results from its Phase 2b RESOLVE trial for eosinophilic esophagitis on November 13.

​The additional 52-week follow-up data from the RESOLVE trial showed all patients in Cohort 6 maintained symptom improvement at week 52 with an average reduction in SDI scores of -3.7 (-58%). Management noted that patients reaching 52 weeks in the trial showed durable symptom relief, which is clinically meaningful.

​Following the announcement, on November 14, Kristen Kluska from Cantor Fitzgerald reiterated a Buy rating on Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) with a price target of C$15.38, reflecting more than 76% upside from the current level.

​Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) is a clinical-stage biotechnology company developing locally delivered, extended-release drug products using its proprietary DiffuSphere technology.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.